WO2014171307A1 - Comprime a dissolution rapide approprie pour une administration a des nourrissons, et son procédé de production simple - Google Patents

Comprime a dissolution rapide approprie pour une administration a des nourrissons, et son procédé de production simple Download PDF

Info

Publication number
WO2014171307A1
WO2014171307A1 PCT/JP2014/059231 JP2014059231W WO2014171307A1 WO 2014171307 A1 WO2014171307 A1 WO 2014171307A1 JP 2014059231 W JP2014059231 W JP 2014059231W WO 2014171307 A1 WO2014171307 A1 WO 2014171307A1
Authority
WO
WIPO (PCT)
Prior art keywords
tablet
disintegrating tablet
disintegrating
production method
pharmaceutical composition
Prior art date
Application number
PCT/JP2014/059231
Other languages
English (en)
Japanese (ja)
Inventor
隆弘 平邑
智仁 岡林
Original Assignee
株式会社ダイセル
ニチリン化学工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社ダイセル, ニチリン化学工業株式会社 filed Critical 株式会社ダイセル
Publication of WO2014171307A1 publication Critical patent/WO2014171307A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Definitions

  • the present invention relates to an intraorally rapidly disintegrating tablet suitable for drug administration to children, a simple production method thereof, and the like.
  • Oral medication to children is difficult because children refuse to take medication. Regardless of whether it is a tablet, powder, or liquid, medication is often unsuccessful due to exhalation without swallowing. In such a case, a vicious cycle of forcibly rejecting the next and subsequent drugs occurs by forcing the drug.
  • Powders and liquids are difficult to administer, while tablets that are relatively easy to administer are difficult to swallow for children and are not practical because of the high risk of aspiration.
  • the difficulty in adjusting the amount of active ingredient is also a drawback of tablets.
  • existing preparations there are still few standards for the amount of active ingredients for children, which is not sufficient.
  • a preparation for adults is used to divide a tablet to adjust the amount of an active ingredient, or it is ground and powdered.
  • Patent Document 1 describes a disintegrating particle composition obtained by uniformly dispersing mannitol, xylitol, an inorganic excipient, a disintegrant, and carmellose in the presence of water and then drying.
  • a characteristic of such a composition is that composite particles are formed by solidly dispersing xylitol in mannitol particles, and an inorganic excipient, a disintegrant and carmellose are dispersed in the composite particles.
  • the disintegrating particle composition is produced by spray granulating a dispersion in which each of these components is dispersed in an aqueous medium, or spraying it on a carrier such as mannitol.
  • Patent Document 2 describes an orally disintegrating tablet containing 10% (w / w) or more of carboxymethylcellulose with respect to the active ingredient and the whole.
  • the orally disintegrating tablet is prepared by a tableting machine after mixing each component.
  • Patent Document 3 describes a method for producing an orally disintegrating tablet containing loratadine, which is a medicinal ingredient.
  • the production method is a two-stage granulation process, wherein in the first granulation process, loratadine and at least one additive such as a binder, an excipient and a disintegrant are granulated, and the second granulation process is performed.
  • the granulation step the granulated product obtained in the first granulation step is further granulated together with at least one additive such as a binder, an excipient, and a disintegrant as in the first granulation step.
  • Carmellose is mentioned as an example of the disintegrant.
  • Patent Document 4 describes a method for producing an orally disintegrating tablet.
  • the production method includes spraying a water suspension of a water-soluble but hydrophilic disintegrating component into a mixture of an excipient and a drug to obtain a granulated product A containing the drug, and the same as the excipient A step of spraying an aqueous suspension of a disintegrating component to obtain a granulated product B containing no drug, and a step of compression-molding the granulated product A and the granulated product B thus obtained.
  • the problem to be solved by the present invention is to easily provide a suitable orally disintegrating tablet that can be easily, reliably and safely administered to a child, and an appropriate amount of an active ingredient in the orally disintegrating tablet. It is to provide a manufacturing method that can be adjusted.
  • the present invention provides the following aspects.
  • a method for producing an orally rapidly disintegrating tablet for children comprising adding a disintegrant additive preparation prepared in advance to a pharmaceutical composition in a powder state, mixing and tableting.
  • the solid pharmaceutical composition is a solid content of an adult tablet or hard capsule.
  • Aspect 5 The production method according to any one of Aspects 2 to 4, wherein the disintegrating additive formulation is added, mixed and tableted without separating and extracting the active ingredient contained in the pharmaceutical composition.
  • Aspect 6 A rapidly disintegrating oral cavity tablet for children obtained by the production method according to any one of Aspects 2 to 5, wherein the oral disintegration time is within 20 seconds. Inner speed disintegrating tablet.
  • the intraoral quick disintegrating tablet of the present invention When the intraoral quick disintegrating tablet of the present invention is administered into the oral cavity, it starts to disintegrate within a very short time, so that the risk of aspiration is also reduced and it is not discharged. As a result, the child does not refuse to take the drug, and the resistance to the drug is reduced. Furthermore, in the method for producing an orally disintegrating tablet of the present invention, the amount of the active ingredient contained in the orally disintegrating tablet can be easily adjusted so that a conventional dosage form can be used for a child to be administered. Can be adjusted.
  • the intraoral quick disintegrating tablet for children according to the present invention is characterized in that the oral disintegration time is 20 seconds, preferably within 15 seconds.
  • the intraoral quick disintegrating tablet of the present invention immediately wets in the oral cavity of the administered child and starts to disintegrate, and is excellent in taste and touch.
  • the hardness of an orally rapidly disintegrating tablet is usually 15 N or more, preferably 30 N or more.
  • Child usually means 7 to 15 years old and “infant” often means 1 to 7 years old.
  • Chiildren generally represent about 1 year old and under 15 years old. Needless to say, the propriety of administration and the amount of the active ingredient to be administered should be determined in consideration of the type of drug, age, weight, symptoms and the like.
  • the “oral disintegration time” is measured by the method described below in this specification.
  • the intraoral rapidly disintegrating tablet of the present invention contains an appropriate amount of any medicinal ingredient (compound) known to those skilled in the art as an active ingredient according to the disease and symptoms to be treated, and has various uses.
  • This medicinal component includes those usually used for adults, those commonly used for adults and children, and those used only for children.
  • nizatidine an H2 receptor antagonist that has a gastric acid secretion inhibitory action
  • an intraoral rapidly disintegrating tablet with a reduced amount of the active ingredient contained therein can be prepared using an adult preparation.
  • diphenhydramine hydrochloride an H1 receptor antagonist that has alleviation of allergic symptoms and sleep-improving action, is not recommended for use in children due to concerns about side effects. Is difficult.
  • an intraoral rapidly disintegrating tablet with a reduced amount of active ingredient can be prepared using an adult preparation.
  • H1 receptor antagonist that has been dry syruped as a dosage form that can be administered to children
  • epinastine hydrochloride is available as a powder or after it is liquefied. , You may be denied medication. If it is judged that an intraoral quick disintegrating tablet is necessary as a dosage form that is easier to administer and less likely to be rejected, use an adult preparation and reduce the amount of active ingredient in the same way. Tablets can be prepared.
  • the rapidly disintegrating tablet in the oral cavity of the present invention in addition to the active ingredient and the disintegrant (disintegrant additive) component, if necessary, an excipient, a fluidizing agent, a surfactant, a lubricant. , And any other pharmaceutically acceptable ingredient such as a sour agent, sweetener, flavoring agent, flavoring agent, coloring agent, and stabilizer.
  • an excipient such as a sour agent, sweetener, flavoring agent, flavoring agent, coloring agent, and stabilizer.
  • any other pharmaceutically acceptable ingredient such as a sour agent, sweetener, flavoring agent, flavoring agent, coloring agent, and stabilizer.
  • a sour agent such as a sour agent, sweetener, flavoring agent, flavoring agent, coloring agent, and stabilizer.
  • the corresponding components described in the Pharmaceutical Additives Dictionary (Pharmaceutical Daily) and the Japanese Pharmacopoeia can be used.
  • Such orally disintegrating tablets can be formulated by any method known to those skilled in the art, such as tableting.
  • the intraoral rapidly disintegrating tablet of the present invention can be produced by a method including adding a disintegrating additive formulation prepared in advance to a pharmaceutical composition in a powder state, mixing and tableting.
  • a disintegrating additive formulation prepared in advance to a pharmaceutical composition in a powder state
  • mixing and tableting there are no particular restrictions on the origin and preparation method of the pharmaceutical composition in the powder state, but it can be obtained, for example, by grinding a solid pharmaceutical composition into a powder.
  • a solid content of the hard capsule is preferable.
  • the amount of the active ingredient suitable for pediatric administration is smaller than that for adults. Therefore, the mixing (solid trituration) operation of such a powdered pharmaceutical composition and a disintegrant additive formulation is effective.
  • the intraoral quick disintegrating tablet of the invention can be produced simply and practically.
  • the pharmaceutical composition in a powder state does not have fast disintegrating properties, and is formulated with a disintegrating additive formulation to impart excellent moldability and disintegrating properties to the intraoral quick disintegrating tablet of the present invention. .
  • Wicking is a disintegration mechanism in which moisture penetrates through components such as a disintegrant contained in a tablet, and as a result, the binding force between particles contained in the tablet weakens and proceeds.
  • Acid type carboxymethyl cellulose is known as a representative example of such a disintegrant having a high effect of promoting wicking.
  • Swelling is a disintegration mechanism in which the disintegrant itself swells and proceeds as a result of water permeating into the disintegrant.
  • the disintegrating additive formulation contains the following substances.
  • carmellose as a disintegrant component
  • an acid type carboxymethyl cellulose used as a pharmaceutical additive can be mentioned.
  • acid-type carboxymethylcellulose for example, calcium salt of carboxymethylcellulose and a crosslinked product of sodium carboxymethylcellulose are both insoluble in water and used as a disintegrant in tablets and the like.
  • sodium salt of carboxymethyl cellulose is water-soluble and is used for the purpose of a binder or the like.
  • the salt of carboxymethylcellulose may be described as carmellose.
  • examples of the second disintegrant component include any disintegrant known to those skilled in the art other than acid-type carboxymethylcellulose.
  • a disintegrant excellent in the effect of promoting swelling as a second disintegrant component other than Wicking, for example.
  • a disintegrant include crospovidone, croscarmellose sodium, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose calcium, hydroxypropyl starch, and starch.
  • Crospovidone is a common name for a crosslinked polymer of 1-vinyl-2-pyrrolidone
  • croscarmellose sodium is a common name for a crosslinked product of sodium carboxymethylcellulose.
  • the third component includes any compound known to those skilled in the art as an excipient.
  • Representative examples thereof include sugars or sugar alcohols such as mannitol, erythritol, sorbitol, D-glutitol (maltitol), xylitol, trehalose, lactose and maltose.
  • preferred examples include mannitol, erythritol, trehalose, sorbitol, and D-glutitol (maltitol).
  • two or more compounds appropriately selected from these can be used.
  • the above-mentioned disintegrating additive formulation contains the above-mentioned three optional ingredients known to those skilled in the art. As long as the effects of the present invention due to the components are not impaired, they may be added and mixed as appropriate. Examples of such components include fluidizing agents, inorganic excipients, sweeteners, fragrances, and coloring agents.
  • the amount of each component in the above-mentioned disintegrant additive formulation depends on the type of each component, the type and use of the active ingredient in the pharmaceutical composition to be mixed, the use of the orally disintegrating tablet as the final product, etc. Thus, those skilled in the art can appropriately determine.
  • the first disintegrant component is 10 to 50% by weight
  • the second disintegrant component is 1 to 20% by weight
  • the excipient is 30 to 89% by weight based on the total weight of the disintegrant additive formulation % Range.
  • said disintegrating additive formulation has the following physical properties. (1) Average particle size: 50 to 200 microns, (2) Water content: 0.5 to 3% by weight.
  • Average particle size 2 g of the disintegrant additive formulation is measured using a ⁇ 75 mm automatic shaking sieve (M-2 type, Tsutsui Rika Instruments Co., Ltd.).
  • Moisture 5 g of disintegrating additive formulation is measured using a halogen moisture meter (HB43 type, METTLER TOLEDO).
  • the method for producing the above-described disintegrating additive formulation there is no particular limitation on the method for producing the above-described disintegrating additive formulation.
  • Said 1st and 2nd granulation process is performed by the method of forming a composite_body
  • a wet granulation method include spraying methods such as spray drying, tumbling granulation, stirring granulation, and fluidized bed granulation, freeze-drying methods, and kneading granulation. It can be produced by any method known to those skilled in the art.
  • disintegrants such as acid-type carboxymethylcellulose are hydrophilic
  • by performing an operation of applying physical force such as stirring in the presence of water by wet granulation particles from the aggregated state at the time of dry powder becomes more dispersed.
  • Fluidized bed granulation for dispersion and drying by water spray, spray drying, tumbling granulation, stirring granulation, etc. can be performed most easily and the drying speed is fast, so these methods are preferable. .
  • the fluidized bed granulation method is a granulation method performed by spraying water or an aqueous solution containing a binder while blowing up the powder with warm air, and it is easy to adjust the spraying conditions and the like. Is the most preferred method.
  • each of the first and second wet granulation processes various conditions such as spraying speed, air supply temperature, exhaust temperature, air supply amount, etc. are determined according to the type and amount of each component.
  • the contractor can decide as appropriate.
  • the spray liquid medium may be any solvent that does not affect the properties of the disintegrating additive formulation and is acceptable for pharmaceuticals and foods. Examples include water, ethanol, methanol, acetone, and the like. Is preferred.
  • the hardness (N) of the intraorally rapidly disintegrating tablet of the present invention was measured three times using a digital hardness meter (KHT-40N, Fujiwara Seisakusho Co., Ltd.). The average value was taken as the measurement result.
  • the disintegration time in the oral cavity one tablet was included in the oral cavity, and the time until the tablet was completely disintegrated was measured while maintaining the state of being sandwiched between the tongue and the upper jaw so as not to apply force. Two adult males were performed twice, and the average value was taken as the measurement result.
  • Carmellose (NS-300, Gotoku Pharmaceutical Co., Ltd.) 100 g, Crospovidone (Polyplastidone INF-10, ISP Japan) 20 g, Mannitol (D-mannitol, Merck Ltd.) 375 g were fluidized bed granulator (LAB-1, The resulting mixture was granulated by spraying 240 g of purified water to obtain a granulated product (disintegrating additive formulation) having an average particle size of about 100 ⁇ m and a water content of about 1%.
  • This nizatidine-containing intraoral rapidly disintegrating tablet has tablet thicknesses of 3.56 mm and 3.85 mm, tablet hardness of 30 N and 16 N, respectively, and oral disintegration time (adult male) when the tableting compression force is 5 kN and 3 kN. They were 15 seconds and 13 seconds, respectively.
  • the amount of nizatidine contained in the intraoral rapidly disintegrating tablet obtained in this example is reduced to about 1/10 (15 mg) of one adult dose (for example, 150 mg) per tablet, It is easy to set the dosage considering the age, weight and symptoms of the children to be dosed.
  • An existing tablet for adults containing 25 mg of diphenhydramine hydrochloride (H1 receptor antagonist) per tablet as an active ingredient (SS Pharmaceutical Co., Ltd. “Driel”, 265 mg tablet weight, croscarmellose sodium as an additive, anhydrous silica 3 tablets (including acid, cellulose, lactose, hydroxypropylcellulose, hypromellose, macrogol, magnesium stearate, talc, titanium oxide) were ground in a mortar to obtain 795 mg of powder containing 75 mg of diphenhydramine hydrochloride.
  • Example 2190 mg of the granulated product obtained by the method of Example 1 and 15 mg of sucralose (Saneigen FFI Co., Ltd.) were added and mixed well in a polyethylene bag.
  • This mixed powder was tableted using a simple tablet molding machine (HANDTAB-100, Ichihashi Seiki Co., Ltd.) at a tableting compression force of 5 kN, and the diameter was 8.0 mm, the plane corner angle was 200 mg, and diphenhydramine per tablet.
  • An intraoral quick disintegrating tablet having a hydrochloride content of 5 mg was obtained.
  • This diphenhydramine hydrochloride-containing intraoral quick disintegrating tablet had a tablet thickness of 3.27 mm, a tablet hardness of 28 N, and an oral disintegration time (adult male) of 17 seconds.
  • the diphenhydramine hydrochloride contained in the intraoral quick disintegrating tablet obtained in the present example is reduced to about 1/10 (5 mg) of one adult dose (for example, 50 mg) per tablet, It is easy to set the dosage considering the age, weight, and symptoms of the child to be administered.
  • This mixed powder was tableted using a simple tablet molding machine (HANDTAB-100, Ichihashi Seiki Co., Ltd.) at a tableting compression force of 7 kN, and the diameter was 8.0 mm, the plane corner angle, the weight was 200 mg, and epinastine per tablet.
  • An intraoral quick disintegrating tablet having a hydrochloride content of 2.5 mg was obtained.
  • This epinastine hydrochloride-containing intraoral rapidly disintegrating tablet had a tablet thickness of 3.37 mm, a tablet hardness of 30 N, and an oral disintegration time (adult male) of 11 seconds.
  • the amount of epinastine hydrochloride contained in the intraoral rapidly disintegrating tablet obtained in this example is reduced to 1/4 (2.5 mg) of the upper limit (10 mg) of the daily standard dose for children per tablet. Therefore, it is easy to set the dosage considering the age, weight, and symptoms of the child to be dosed.
  • an intraoral quick disintegrating tablet that can be easily, reliably, and safely administered to children and the amount of an active ingredient is appropriately adjusted, and is readily available and has existing quick disintegrating properties.
  • a practical production method for simply producing the orally disintegrating tablet from an unadulterated tablet is provided.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention vise à proposer : un comprimé à dissolution orale approprié pouvant être administré facilement, de façon fiable et en toute sécurité à des nourrissons ; et un procédé de production de celui-ci, dans lequel une quantité de composant efficace appropriée du comprimé à dissolution orale peut être ajustée facilement. La présente invention concerne : un procédé de production pour un comprimé à dissolution rapide orale pour des nourrissons, comprenant l'ajout d'un additif de dissolution pré-préparé mélangé à une composition pharmaceutique en poudre, le mélange de celui-ci et la préparation de comprimés ; et un comprimé à dissolution rapide orale, etc., pour des nourrissons, caractérisé par le temps de dissolution orale inférieur ou égal à 20 secondes.
PCT/JP2014/059231 2013-04-16 2014-03-28 Comprime a dissolution rapide approprie pour une administration a des nourrissons, et son procédé de production simple WO2014171307A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013-085395 2013-04-16
JP2013085395A JP2016117652A (ja) 2013-04-16 2013-04-16 小児への投与に適した速崩壊錠とその簡便な製造方法

Publications (1)

Publication Number Publication Date
WO2014171307A1 true WO2014171307A1 (fr) 2014-10-23

Family

ID=51731259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/059231 WO2014171307A1 (fr) 2013-04-16 2014-03-28 Comprime a dissolution rapide approprie pour une administration a des nourrissons, et son procédé de production simple

Country Status (3)

Country Link
JP (1) JP2016117652A (fr)
TW (1) TW201446287A (fr)
WO (1) WO2014171307A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017101007A (ja) * 2015-12-04 2017-06-08 株式会社ダイセル 口腔内崩壊性シート状製剤
CN108136035A (zh) * 2015-09-04 2018-06-08 株式会社大赛璐 超速崩解片剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002185A1 (fr) * 1996-07-12 1998-01-22 Daiichi Pharmaceutical Co., Ltd. Materiaux moules par compression, a desagregation rapide, et leur procede de production
JP2001163770A (ja) * 1999-12-08 2001-06-19 Yansen Kyowa Kk 口腔内速崩壊型錠剤及びその製造方法
JP2002179558A (ja) * 2000-10-06 2002-06-26 Takeda Chem Ind Ltd 固形製剤
JP2010540588A (ja) * 2007-10-01 2010-12-24 ラボラトリオス、レスビ、ソシエダッド、リミターダ 口腔内崩壊錠剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002185A1 (fr) * 1996-07-12 1998-01-22 Daiichi Pharmaceutical Co., Ltd. Materiaux moules par compression, a desagregation rapide, et leur procede de production
JP2001163770A (ja) * 1999-12-08 2001-06-19 Yansen Kyowa Kk 口腔内速崩壊型錠剤及びその製造方法
JP2002179558A (ja) * 2000-10-06 2002-06-26 Takeda Chem Ind Ltd 固形製剤
JP2010540588A (ja) * 2007-10-01 2010-12-24 ラボラトリオス、レスビ、ソシエダッド、リミターダ 口腔内崩壊錠剤

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108136035A (zh) * 2015-09-04 2018-06-08 株式会社大赛璐 超速崩解片剂及其制备方法
US10864165B2 (en) * 2015-09-04 2020-12-15 Daicel Corporation Super-rapid disintegrating tablet, and method for producing same
JP2017101007A (ja) * 2015-12-04 2017-06-08 株式会社ダイセル 口腔内崩壊性シート状製剤

Also Published As

Publication number Publication date
TW201446287A (zh) 2014-12-16
JP2016117652A (ja) 2016-06-30

Similar Documents

Publication Publication Date Title
KR101465803B1 (ko) 구강내 붕괴 정제
TWI639446B (zh) 含有酸性羧甲基纖維素及結晶纖維素之崩解性粒子組成物以及含有該組成物之口腔內崩解錠劑
JP2019131597A (ja) 超速崩壊錠剤及びその製造方法
TWI673069B (zh) 超高速崩解錠劑及其製造方法
US10864165B2 (en) Super-rapid disintegrating tablet, and method for producing same
WO2014171307A1 (fr) Comprime a dissolution rapide approprie pour une administration a des nourrissons, et son procédé de production simple
JP6476122B2 (ja) 二段階の湿式造粒工程で製造される崩壊性粒子組成物及び該組成物を含む口腔内崩壊錠剤
JP5275815B2 (ja) リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤
TWI644688B (zh) 含有崩解性粒子組成物之口腔內崩解錠劑之製造方法
WO2014171306A1 (fr) Comprimé à désintégration rapide pour administration à des animaux de petite taille et son procédé de fabrication simple
TW201609193A (zh) 含有碳酸鹽之口腔內崩解錠劑用組成物及口腔內崩解錠劑
TW202135802A (zh) 包含吡咯羧醯胺之口腔崩散錠
Anees-Ur-Rahaman Formulation and Evaluation of Fast Dissolving Tablets of Anti-Asthmatic Drug

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14785512

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14785512

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP